002287:SZSETibet Cheezheng Tibetan Medicine Co., Ltd. Analysis

The stock is trading at CNY 20.11, just above the calculated support of 19.89 and below the 20‑day SMA of 21.17, signaling a fragile price level. Technical indicators are bearish: RSI sits at 31, MACD histogram is negative and the trend direction is marked bearish, while volume is increasing, suggesting pressure may intensify. Fundamentally, the company reports an impressive gross margin of 83% and operating margin of 22%, reflecting strong pricing power in its niche Tibetan medicine market. However, free cash flow is negative and the DCF fair value of roughly CNY 8.3 is far below the current price, indicating potential overvaluation. The trailing PE of 16.5 is well under the industry average of 24.9, offering a relative value argument, yet the dividend yield of 4.98% with a 49% payout ratio raises questions about sustainability given the cash flow gap. Debt levels are modest in absolute terms but the debt‑to‑equity ratio appears high, adding a layer of balance‑sheet risk. Overall, the stock presents a mixed picture: solid profitability and attractive yield on one side, but bearish momentum, valuation disconnect, and cash‑flow concerns on the other.